That was before the spectacular success of Hemlibra, a bispecific antibody-based drug that mimics the function of Factor VIII by bridging clotting factors on either side of it in the clotting pathway.

Sanofi and Sobi's haemophilia partnership has been under competitive pressure from new therapies like Roche's antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate ...

The top four growth drivers — Vabysmo, Phesgo, Ocrevus and Hemlibra — achieved total sales of CHF 16.9 billion, reflecting an increase of CHF 3.3 billion from that recorded in 2023.